NewAmsterdam Pharma N.V.
(NAMS)
undefined
undefined%
At close: undefined
24.00
-2.00%
After-hours Dec 13, 2024, 05:54 PM EST
Company Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C).
The company was founded in 2019 and is based in Naarden, the Netherlands.
NewAmsterdam Pharma N.V.
| Country | NL |
| IPO Date | Feb 9, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Dr. Michael Harvey Davidson FACC, Facp., M.D. |
Contact Details
Address: Gooimeer 2-35 Naarden, NL | |
| Website | https://www.newamsterdampharma.com |
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| CUSIP Number | n/a |
| ISIN Number | NL00150012L7 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President, Executive Board Member & Director |
| Douglas F. Kling | Chief Operating Officer |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Bob Rambo | Executive Vice President of Marketing |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
| Dr. Sheng Cui Ph.D. | Chief Manufacturing Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Business Officer |
| Louise Kooij | Chief Accounting Officer |
| Matthew Philippe | Executive Vice President &Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 424B5 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 11, 2024 | S-3MEF | Filing |
| Dec 10, 2024 | 424B5 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 4 | Filing |
| Nov 18, 2024 | 8-K | Current Report |